0.20
-0.0168(-7.69%)
Currency In USD
| Previous Close | 0.22 |
| Open | 0.21 |
| Day High | 0.21 |
| Day Low | 0.19 |
| 52-Week High | 2.28 |
| 52-Week Low | 0.19 |
| Volume | 2.73M |
| Average Volume | 1.5M |
| Market Cap | 1.76M |
| PE | -0.14 |
| EPS | -1.46 |
| Moving Average 50 Days | 1 |
| Moving Average 200 Days | 1.41 |
| Change | -0.02 |
If you invested $1000 in BioRestorative Therapies, Inc. (BRTX) 10 years ago, it would be worth $0.01 as of February 23, 2026 at a share price of $0.199. Whereas If you bought $1000 worth of BioRestorative Therapies, Inc. (BRTX) shares 5 years ago, it would be worth $2.97 as of February 23, 2026 at a share price of $0.199.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
BioRestorative Announces Closing of $5.0 Million Public Offering
GlobeNewswire Inc.
Feb 14, 2026 1:30 AM GMT
MELVILLE, N.Y., Feb. 13, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a late stage clinical regenerative medicine innovator focused on stem cell-based therapies and products, tod
BioRestorative Announces Pricing of $5.0 Million Public Offering
GlobeNewswire Inc.
Feb 12, 2026 3:30 AM GMT
MELVILLE, N.Y., Feb. 11, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a late stage clinical regenerative medicine innovator focused on stem cell-based therapies and products, tod
BioRestorative Announces Positive Outcome from Type B Meeting with FDA
GlobeNewswire Inc.
Feb 11, 2026 12:30 PM GMT
BioRestorative completed a Type B meeting with the U.S. Food and Drug Administration (“FDA”) regarding a potential accelerated Biologics License Application (“BLA”) approval pathway for the Fast-Track-Designated BRTX-100 program for the treatment of